home.social

#revenueforecast — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #revenueforecast, aggregated by home.social.

  1. QUALCOMM'S FUTURE UNCERTAIN AS REVENUE FORECAST MISSES TARGETS

    Qualcomm's Q3 revenue forecast misses targets due to chip shortages, impacting Chinese handset market. CEO sees future recovery.

    #Qualcomm, #ChipShortage, #TechNews, #RevenueForecast, #ChineseMarket

    newsletter.tf/qualcomm-revenue

  2. Qualcomm's Q3 revenue forecast missed expectations, showing a significant impact from the global chip shortage. This is a big change from previous predictions.

    #Qualcomm, #ChipShortage, #TechNews, #RevenueForecast, #ChineseMarket
    newsletter.tf/qualcomm-revenue

  3. Macy's Inc. lowered its full-year profit outlook due to tariff uncertainty under the Trump administration, despite first-quarter earnings and revenue beating market expectations and shares rising over 3% in pre-market trading.
    #YonhapInfomax #MacysInc #EarningsPerShare #TrumpTariffs #StoreClosures #RevenueForecast #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
    en.infomaxai.com/news/articleV

  4. Microchip Technology plans to close its Tempe, AZ plant in Q3 2025, affecting 500 employees, and lowers its Q3 revenue forecast. ⚠️ #MicrochipTechnology #Tempe #Manufacturing #TechNews #Q3Forecast #BusinessNews #EmploymentImpact #RevenueForecast

  5. Strong demand for Botox, generating $1.49 billion in quarterly revenue, persists despite intense competition. AbbVie's 2024 earnings per share forecast falls in the range of $11.05 - $11.25 billion, aligning with analyst estimates at the upper end of this range, specifically at $11.24. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  6. Strong demand for Botox, generating $1.49 billion in quarterly revenue, persists despite intense competition. AbbVie's 2024 earnings per share forecast falls in the range of $11.05 - $11.25 billion, aligning with analyst estimates at the upper end of this range, specifically at $11.24. #AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  7. The negative outlook stemming from CVS Health's decision to delist Humira poses a challenge, but AbbVie aims to counter the lost revenue with new immunology products Skyrizi and Rinvoq. In its 2027 projection, AbbVie raised the revenue forecast for these drugs from $21 billion to $27 billion.#AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations

  8. The negative outlook stemming from CVS Health's decision to delist Humira poses a challenge, but AbbVie aims to counter the lost revenue with new immunology products Skyrizi and Rinvoq. In its 2027 projection, AbbVie raised the revenue forecast for these drugs from $21 billion to $27 billion.#AbbVie #FinancialResults #EarningsReport #Humira #ImmunologyProducts #Botox #RevenueForecast #2024Projection #MarketExpectations